C. Maloney, M. P. Kallis, M. Symons, B. M. Steinberg, The Elmezzi Graduate School of Molecular Medicine, Northwell Health, Manhasset, NY, USA C. Maloney, M. P. Kallis, S. Z. Soffer, M. Symons, B. M. Steinberg, Karches Center for Oncology Research, The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, USA C. Maloney, M. P. Kallis, S. Z. Soffer, Department of Surgery, Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, USA M. C. Edelman, Department of Pathology and Laboratory Medicine, Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY, USA.
Clin Orthop Relat Res. 2018 Jul;476(7):1514-1522. doi: 10.1007/s11999.0000000000000291.
Although metastasis is the major cause of mortality in patients with osteosarcoma, little is known about how micrometastases progress to gross metastatic disease. Clinically relevant animal models are necessary to facilitate development of new therapies to target indolent pulmonary metastases. Intratibial injection of human and murine osteosarcoma cell lines have been described as orthotopic models that develop spontaneous pulmonary metastasis over time. However, there is variability in reported injection techniques and metastatic efficiency.
QUESTIONS/PURPOSES: We aimed to characterize a widely used murine model of metastatic osteosarcoma, determine whether it is appropriate to study spontaneous pulmonary metastasis by establishing a reliable volume for intratibial injection, determine the incidence of primary tumor and metastatic formation, determine the kinetics of pulmonary metastatic seeding and outgrowth, and the contribution of the primary tumor to subsequent development of metastasis.
The metastatic mouse osteosarcoma cell line K7M2 was injected into the tibia of mice. The maximum volume that could be injected without leakage was determined using Evan's blue dye (n = 8 mice). Primary tumor formation and metastatic efficiency were determined by measuring the incidence of primary tumor and metastatic formation 4 weeks after intratibial injection (n = 30). The kinetics of metastatic development were determined by performing serial euthanasia at 1, 2, 3, and 4 weeks after injection (n = 24; five to six mice per group). Number of metastatic foci/histologic lung section and metastatic burden/lung section (average surface area of metastatic lesions divided by the total surface area of the lung) was calculated in a blinded fashion. To test the contribution of the primary tumor to subsequent metastases, amputations were performed 30 minutes, 4 hours, or 24 hours after injection (n = 21; five to six mice per group). Mice were euthanized after 4 weeks and metastatic burden calculated as described previously, comparing mice that had undergone amputation with control, nonamputated mice. Differences between groups were calculated using Kruskal-Wallis and one-way analysis of variance.
The maximum volume of cell suspension that could be injected without leakage was 10 μL. Intratibial injection of tumor cells led to intramedullary tumor formation in 93% of mice by 4 weeks and resulted in detectable pulmonary metastases in 100% of these mice as early as 1 week post-injection. Metastatic burden increased over time (0.88% ± 0.58, week 1; 6.6% ± 5.3, week 2; 16.1% ± 12.5, week 3; and 40.3% ± 14.83, week 4) with a mean difference from week 1 to week 4 of -39.38 (p < 0.001; 95% confidence interval [CI], -57.39 to -21.37), showing pulmonary metastatic growth over time. In contrast, the mean number of metastatic foci did not increase from week 1 to week 4 (36.4 ± 33.6 versus 49.3 ± 26.3, p = 0.18). Amputation of the injected limb at 30 minutes, 4 hours, and 24 hours after injection did not affect pulmonary metastatic burden at 4 weeks, with amputation as early as 30 minutes post-injection resulting in a metastatic burden equivalent to tumor-bearing controls (48.9% ± 6.1% versus 40.9% ± 15.3%, mean difference 7.96, p = 0.819; 95% CI, -33.9 to 18.0).
There is immediate seeding of the metastatic site after intratibial injection of the K7M2 osteosarcoma cell line, independent of a primary tumor. This is therefore not a model of spontaneous metastasis.
This model should not be used to study the early components of the metastatic cascade, but rather used as an experimental model of metastasis. Improved understanding of this commonly used model will allow for proper interpretation of existing data and inform the design of future studies exploring the biology of metastasis in osteosarcoma.
尽管转移是骨肉瘤患者死亡的主要原因,但对于微转移如何进展为大转移疾病知之甚少。有必要建立临床相关的动物模型,以开发针对惰性肺转移的新疗法。胫骨内注射人源和鼠源骨肉瘤细胞系已被描述为一种自发发生肺转移的原位模型。然而,报道的注射技术和转移效率存在差异。
我们旨在描述一种广泛使用的转移性骨肉瘤鼠模型,确定通过建立可靠的胫骨内注射体积来研究自发性肺转移是否合适,确定原发性肿瘤和转移性形成的发生率,确定肺转移性播散和生长的动力学,以及原发性肿瘤对随后转移形成的贡献。
将转移性鼠骨肉瘤细胞系 K7M2 注射到小鼠的胫骨中。使用 Evan's 蓝染料确定最大无泄漏注射体积(n = 8 只小鼠)。通过测量胫骨内注射后 4 周原发性肿瘤和转移性形成的发生率来确定原发性肿瘤形成和转移性效率(n = 30)。通过在注射后 1、2、3 和 4 周进行连续安乐死来确定转移性发展的动力学(n = 24;每组 5-6 只小鼠)。在盲法下计算每只肺组织切片的转移灶数量/组织学肺切片和转移负荷/肺切片(转移灶的平均表面积除以肺的总表面积)。为了测试原发性肿瘤对随后转移的贡献,在注射后 30 分钟、4 小时或 24 小时进行截肢(n = 21;每组 5-6 只小鼠)。4 周后处死小鼠,并按照先前描述的方法计算转移负荷,比较接受截肢和未接受截肢的对照组小鼠。使用 Kruskal-Wallis 和单因素方差分析计算组间差异。
无泄漏注射的最大细胞悬液体积为 10 μL。胫骨内注射肿瘤细胞导致 93%的小鼠在 4 周内形成髓内肿瘤,并在注射后 1 周内导致 100%的小鼠可检测到肺转移。转移负荷随时间增加(第 1 周 0.88% ± 0.58;第 2 周 6.6% ± 5.3;第 3 周 16.1% ± 12.5;第 4 周 40.3% ± 14.83),第 1 周至第 4 周的平均差异为-39.38(p < 0.001;95%置信区间,-57.39 至-21.37),表明肺转移性生长随时间增加。相比之下,从第 1 周到第 4 周,转移灶的平均数量没有增加(36.4 ± 33.6 与 49.3 ± 26.3,p = 0.18)。在注射后 30 分钟、4 小时和 24 小时进行截肢,不会影响 4 周时的肺转移负荷,在注射后 30 分钟进行截肢,转移负荷与肿瘤携带对照组相当(48.9% ± 6.1%与 40.9% ± 15.3%,平均差异 7.96,p = 0.819;95%置信区间,-33.9 至 18.0)。
在 K7M2 骨肉瘤细胞系胫骨内注射后,转移部位立即发生播种,与原发性肿瘤无关。因此,这不是自发性转移的模型。
该模型不应用于研究转移级联的早期成分,而应作为转移的实验模型。对这种常用模型的更好理解将允许对现有数据进行适当的解释,并为探索骨肉瘤转移生物学的未来研究提供信息。